The Accelerating Medicines Partnership in Parkinson’s Disease (AMP PD; https://amp-pd.org) aims to identify and validate diagnostic, prognostic, and progression biomarkers for Parkinson’s Disease (PD). The AMP PD workbench includes sharing of harmonized molecular (e.g. RNA sequencing, whole genome sequencing, transcriptomics) and clinical data identify new targets, disease subtypes, and predictive markers for PD progression and prognosis. AMP PD uses well-characterized cohorts with biosamples and clinical data that were collected under comparable protocols. Seven unified cohorts are currently included in AMP PD and described here.
AMP PD’s tiered access cloud-native platform, built using the Terra application, fosters sharing of tools and data, supports nimble data analysis, decreases storage and compute costs, and facilitates inter-institutional collaboration to enable the discovery of diagnostic, prognostic, and progression biomarkers for PD clinical trial design and therapeutic development. The platform includes a data explorer with a public UI for researchers to easily explore datasets.
As of March 2021, AMP PD includes harmonized clinical data from 10,247 participants across 7 cohorts. Modalities available include longitudinal and cross-sectional clinical data, longitudinal blood-based transcriptomics, RNA sequencing, and whole genome sequencing data. Future datasets scheduled for release in 2021 will include proteomic analyses in plasma and cerebrospinal fluid.